Stuttgart - Delayed Quote EUR

1NE.SG,0P0001K8KH,0 (1NE.SG)

6.74

+0.28

+(4.26%)

At close: July 23 at 10:00:00 PM GMT+2

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease

GlobeNewswire 11 days ago

VRCA
Verrica Provides Business and Operational Update

-- Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure -- Observed significant reduction in YCANTH distributor inventory levels -- New single applicator configuration for YCANTH® expected to be available in the first quarter of 2025 to help meet growing product demand, reduce acquisition costs for physician practices and expand distribution and patient access -- Continue to

GlobeNewswire last month

VRCA
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee granted David Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effective December 9, 2024. The stock

GlobeNewswire last month

VRCA
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced its development and commercialization partner, Torii Pharmaceutical Co. Ltd. (“Torii”), submitted a New Drug Application (“NDA”) of TO-208 (referred to as VP-102 and marketed as YCANTH® in the U.S.) for the treatment of Molluscum Contagiosum (“moll

GlobeNewswire last month

VRCA
Verrica Announces Pricing of $42.0 Million Public Offering

WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, acco

GlobeNewswire 2 months ago

VRCA
Verrica Announces Proposed Public Offering

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering.

GlobeNewswire 2 months ago

VRCA
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership

GlobeNewswire 2 months ago

VRCA
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of two abstracts that will be presented as posters a

GlobeNewswire 3 months ago

VRCA
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operati

GlobeNewswire 3 months ago

VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. H.C. Wainwright 26th Annual Global Investment C

GlobeNewswire 4 months ago

VRCA
When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?

We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears the...

Simply Wall St. 5 months ago

VRCA
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHEST

GlobeNewswire 5 months ago

VRCA
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is ex

GlobeNewswire 5 months ago

VRCA
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the

GlobeNewswire 5 months ago

VRCA
3 High Insider Ownership US Stocks With Up To 52% Revenue Growth

As the U.S. stock market experiences fluctuations with major indices showing minimal changes and investors anticipating rate cuts, it's a critical time to consider the stability and potential growth of companies. High insider ownership can be a strong signal of confidence in a company's future, particularly in such uncertain market conditions.

Simply Wall St. 6 months ago

VRCA

HSAI

CCB
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of lit

GlobeNewswire 6 months ago

VRCA
High Insider Ownership Growth Stocks On US Exchange For June 2024

As the U.S. stock market experiences fluctuations, with recent slips in major indices like the Dow Jones, S&P 500, and Nasdaq from record highs, investors are keenly observing market dynamics and economic indicators such as inflation rates and interest rate expectations. In this context, examining growth companies with high insider ownership might offer valuable insights, as these firms often demonstrate a strong alignment between management's interests and shareholder returns.

Simply Wall St. 7 months ago

VRCA

HSAI

EH
Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders

Key Insights Insiders appear to have a vested interest in Verrica Pharmaceuticals' growth, as seen by their sizeable...

Simply Wall St. 7 months ago

VRCA
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, New York, June 6, 2024.Even

GlobeNewswire 7 months ago

VRCA
High Insider Ownership Growth Companies On US Exchange May 2024

Amidst a backdrop of economic cooling and fluctuating market conditions, the U.S. stock market has shown resilience with signs that rate cuts could be on the horizon, potentially buoying investor sentiment. In this context, companies with high insider ownership can be particularly compelling as they often signal strong confidence from those closest to the company's operations and future prospects.

Simply Wall St. 7 months ago

TBPH

ALGT

VRCA

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

1NE.SG,0P0001K8KH,0 (1NE.SG)

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Verrica Provides Business and Operational Update

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Announces Proposed Public Offering

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

3 High Insider Ownership US Stocks With Up To 52% Revenue Growth

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

High Insider Ownership Growth Stocks On US Exchange For June 2024

Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

High Insider Ownership Growth Companies On US Exchange May 2024